CQN-MA-RENAGADE
29.4.2024 23:01:34 CEST | Business Wire | Press release
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center, which was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and to unlock the delivery of short and long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” GanNA founders Bertozzi and Cummings will now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients.” Dr. Cummings noted that “Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TrailRunner International Names Alden Mitchell as President of TrailRunner Sports17.3.2026 14:03:00 CET | Press release
Proven global business leader brings more than two decades of experience in sports, media, and technology with a track record of success at iconic brands including Uber, Viacom, Discovery, collegiate conferences, and Stanford University TrailRunner International today announced that Alden Mitchell has been named President of TrailRunner Sports, the firm’s global sports advisory business. Most recently Chief Operating Officer of Stanford Athletics, Mitchell will accelerate the growth and expansion of TrailRunner Sports, which was established to provide strategic business advisory and communications support to global sports clients spanning leagues, teams, conferences, educational institutions, ownership groups, athletes, investors, and brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317576708/en/ Alden Mitchell, President of TrailRunner Sports Since its launch in 2023, TrailRunner Sports has seen significant growth
Qualcomm Increases Quarterly Cash Dividend and Announces New $20 Billion Stock Repurchase Authorization17.3.2026 14:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.89 to $0.92 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 26, 2026, and will raise the annualized dividend payout to $3.68 per share of common stock. Additionally, the Board of Directors has approved, effective immediately, a new $20.0 billion stock repurchase authorization. The new stock repurchase authorization is in addition to the Company’s stock repurchase program announced in November 2024, which has approximately $2.1 billion of repurchase authority remaining. The new stock repurchase program has no expiration date. The timing of stock repurchases and the number of shares of common stock to be repurchased will depend upon prevailing market conditions and other factors. Repurchases under this program may be commenced or suspended from time-to-time at the Company’
Lwart Environmental Solutions Expands Long-Standing Relationship with Rimini Street, Consolidating Support for VMware and SAP to Regain Control of Licensing and Roadmap Decisions17.3.2026 14:00:00 CET | Press release
Brazilian oil re‑refinery avoids forced upgrades, stabilizes core systems and redirects IT savings toward business innovation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Lwart Environmental Solutions, one of the world’s leading oil re-refineries and industrial sustainability organizations, has expanded its long-time partnership with Rimini Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317697393/en/ Lwart Environmental Solutions Expands Long-Standing Relationship with Rimini Street, Consolidating Support for VMware and SAP to Regain Control of Licensing and Roadmap Decisions By switching to Rimini Street for SAP and VMware support, Lwart has taken direct control of its software licensing, upgrade and technology roadmap decisions, eliminating vendor-driven timelines and cost es
Lenovo Partners with Eva Longoria to Launch Global Search for Business “Twins”17.3.2026 14:00:00 CET | Press release
Backing Every Business initiative pairs founders with mentorship, grants and AI-powered technology - because no small business owner should build alone.Eva Longoria is ready to be your “business twin;” entrepreneurs worldwide can apply to be mentored directly by her. Applications are open now. Lenovo today launches Backing Every Business, a new global initiative designed to close the support gap facing small businesses. In partnership with actress, entrepreneur and investor Eva Longoria, founders around the world can apply for grant funding, AI-enabled technology and one-to-one mentorship, including from Longoria herself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317068350/en/ Small and medium-sized businesses fuel the world’s economy, representing approximately 90% of all businesses, 70% of employees and 50% of global GDP, according to the World Economic Forum. Their impact is anything but small, yet many founders s
SLB OneSubsea Awarded Integrated EPC Contract for Deepwater Development17.3.2026 13:30:00 CET | Press release
Award adds to OneSubsea’s project pipeline and reinforces its standardized system design Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a multi-well, integrated engineering, production, and construction (EPC) contract by China National Offshore Oil Corporation (CNOOC). The contract encompasses 20 wells and covers the delivery of integrated subsea production systems for the deepwater Kaiping 18-1 field development in the South China Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317076557/en/ SLB OneSubsea will deliver standardized subsea production technology that includes dual electric submersible pump (ESP), gas lift and gas injection horizontal trees, manifolds, connectors, and control systems, along with installation and commissioning support. Under the contract, SLB OneSubsea will deliver standardized subsea production technology that includes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom